Sensorion FY26 H1 net loss widens to €20.71 million; R&D expenses rise 9% to €16.4 million
Bitget2026/09/23 05:30- Sensorion posted a first-half net loss of €20.71 million, widening from €16.01 million a year earlier under IFRS.
- R&D expenses rose 9% to €16.4 million, while G&A costs climbed to €7.69 million from €4.14 million.
- Cash, cash equivalents and short-term deposits reached €88 million at June 30, up from €47.5 million at end-2025.
- ANSM authorized the Phase I/II HearConnex trial of SENS-601 in France; first patient dosing is expected by early 2027.
- Guidance calls for funding through end-2027, with SENS-601 IND submission in the U.S. and an Australia CTA by year-end 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Crypto prices
More
